Mezigdomide plus dexamethasone show ‘preliminary efficacy’ for refractory multiple myeloma
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Four distinct Kawasaki disease subgroups identified
Distinct subgroups exist among children with Kawasaki disease, say researchers in findings that provide some clues to the clinical variability of the disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cushing’s syndrome comorbidities require surveillance beyond remission
Experts emphasize the need for long-term surveillance for all patients with Cushing’s syndrome, after their systematic literature review showed associated comorbidities often continue well beyond remission.
Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Raised neutrophil count linked to amyotrophic lateral sclerosis onset
Increased neutrophil levels may be associated with an increased risk of developing amyotrophic lateral sclerosis, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intra-arterial chemotherapy approach shows promise for advanced unilateral retinoblastoma
The likelihood of successful globe salvage for children with advanced unilateral retinoblastoma is higher with intra-arterial chemotherapy than with a conventional intravenous approach, randomised trial findings suggest.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Base-edited CAR T-cell therapy shows promise for relapsed, refractory childhood ALL
Base-edited chimeric antigen receptor T-cell therapy is feasible for the treatment of relapsed or refractory childhood T-cell acute lymphoblastic leukemia, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Brain imaging aids long-term outcome prediction in paediatric cardiac arrest
Research suggests that magnetic resonance imaging and magnetic resonance spectroscopy conducted within 2 weeks of a cardiac arrest may help determine longer-term outcomes in children.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Add-on tofacitinib shows treatment promise in SSc-ILD
The addition of tofacitinib to conventional disease-modifying antirheumatic drugs could help alleviate sclerosis in patients with systemic sclerosis-associated interstitial lung disease, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cortical gyrification a possible early biomarker for PD progression
Researchers have found reductions in cortical gyrifications in patients with newly diagnosed Parkinson’s disease that worsen over time and may therefore serve as a potential biomarker for disease progression.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
